Agios Pharmaceuticals (AGIO) Cost of Revenue (2018 - 2026)

Agios Pharmaceuticals' Cost of Revenue history runs 8 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• Quarterly Cost of Revenue rose 21.57% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (up 42.31% YoY) and the FY2025 annual result came in at $6.3 million, up 52.34% from the prior year.
• Cost of Revenue was $1.3 million for Q1 2026 at Agios Pharmaceuticals, down from $1.9 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $1.9 million in Q4 2025 and bottomed at $339000.0 in Q1 2022.
• A 5-year average of $965529.4 and a median of $783000.0 in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2023 — Cost of Revenue jumped 154.71% — and 2024, when it rose 13.18%.
• Agios Pharmaceuticals' Cost of Revenue stood at $413000.0 in 2022, then jumped by 41.89% to $586000.0 in 2023, then jumped by 115.02% to $1.3 million in 2024, then jumped by 49.13% to $1.9 million in 2025, then decreased by 29.8% to $1.3 million in 2026.
• Business Quant data shows AGIO's Cost of Revenue at $1.3 million in Q1 2026, $1.9 million in Q4 2025, and $1.7 million in Q3 2025.